Published in Medical Letter on the CDC and FDA, July 30th, 2006
AbbeyMoor has developed The Spanner prostatic stent, which is designed to manage prostatic obstruction in men. AbbeyMoor recently completed a multicenter clinical trial and is progressing with the pre-market approval (PMA) process with the U.S. Food & Drug Administration (FDA). The PMA was filed with the FDA in March 2006. SurModics has licensed its polymer matrix technology to enhance the Spanner platform to incorporate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.